Nianli Liu

Publication Activity (10 Years)

Years Active: 2019-2022
Publications (10 Years): 6

Top Topics

Renal Cell Carcinoma

Small Cell Lung Cancer

Top Venues

Journal of cellular and molecular medicine

Journal of clinical and translational hepatology

OncoTargets and therapy

Medical oncology (Northwood, London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Rui Zhang, Wei Wang, Nie Zhang, Xueting Chen, Wanming Liu, Longzhen Zhang, Nianli Liu
Systematic pan-cancer analysis identifies RBM39 as an immunological and prognostic biomarker. Journal of cellular and molecular medicine 26 (18) (2022)
Wei Wang, Rui Zhang, Ning Feng, Longzhen Zhang, Nianli Liu
Overexpression of RBM34 Promotes Tumor Progression and Correlates with Poor Prognosis of Hepatocellular Carcinoma. Journal of clinical and translational hepatology 11 (2) (2022)
Wei Wang, Rui Zhang, Ning Feng, Longzhen Zhang, Nianli Liu
Overexpression of RBM34 Promotes Tumor Progression and Correlates with Poor Prognosis of Hepatocellular Carcinoma. Journal of clinical and translational hepatology 11 (2) (2022)
Nianli Liu, Aoxing Chen, Ning Feng, Xiaochen Liu, Longzhen Zhang
SNRPB is a mediator for cellular response to cisplatin in non-small-cell lung cancer. Medical oncology (Northwood, London, England) 38 (5) (2021)
Liantao Li, Na Li, Nianli Liu, Fuchun Huo, Junnian Zheng
MBD2 Correlates with a Poor Prognosis and Tumor Progression in Renal Cell Carcinoma. OncoTargets and therapy 13 (2020)
Nianli Liu, Zhiyuan Wu, Aoxing Chen, Dafei Chai, Liantao Li, Longzhen Zhang, Jun-Nian Zheng
ISG12a and its interaction partner NR4A1 are involved in TRAIL-induced apoptosis in hepatoma cells. Journal of cellular and molecular medicine 23 (5) (2019)